<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2014-06-06">6 June 2014</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">G</forename><surname>Maschmeyer</surname></persName>
							<email>gmaschmeyer@klinikumevb.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology, Oncology and Palliative Care</orgName>
								<orgName type="institution">Klinikum Ernst von Bergmann</orgName>
								<address>
									<settlement>Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="institution">The Christie NHS Foundation Trust</orgName>
								<address>
									<settlement>Manchester</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Carratalà</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Infectious Diseases</orgName>
								<orgName type="institution" key="instit1">Bellvitge University Hospital</orgName>
								<orgName type="institution" key="instit2">University of Barcelona</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff15">
								<orgName type="department">Clinical and Experimental Pharmacology</orgName>
								<orgName type="institution">The Paterson Institute for Cancer Research</orgName>
								<address>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Buchheidt</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<orgName type="institution">Mannheim University Hospital</orgName>
								<address>
									<settlement>Mannheim</settlement>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="institution">Charité Comprehensive Cancer Center</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Hamprecht</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Institution for Medical Microbiology, Immunology and Hygiene</orgName>
								<orgName type="institution">University Hospital Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Heussel</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Diagnostic and Interventional Radiology with Nuclear Medicine</orgName>
								<orgName type="institution">University Hospital</orgName>
								<address>
									<settlement>Thoraxklinik, Heidelberg</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Kahl</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<address>
									<addrLine>Klinikum Magdeburg</addrLine>
									<settlement>Magdeburg</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Lorenz</surname></persName>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Department of Pneumology</orgName>
								<orgName type="department" key="dep2">Infectious Diseases, Sleep Medicine and Intensive Care</orgName>
								<orgName type="institution">Klinikum Lüdenscheid</orgName>
								<address>
									<settlement>Lüdenscheid</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Neumann</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Medical Oncology</orgName>
								<orgName type="institution">AMO MVZ</orgName>
								<address>
									<settlement>Wolfsburg</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Rieger</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Medicine III</orgName>
								<orgName type="institution">University Hospital Großhadern</orgName>
								<address>
									<settlement>München</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Ruhnke</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Medical Oncology and Hematology</orgName>
								<orgName type="institution">Charité University Medicine Campus Mitte</orgName>
								<address>
									<settlement>Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><surname>Salwender</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Hematology, Oncology</orgName>
								<orgName type="institution" key="instit1">Stem Cell Transplantation</orgName>
								<orgName type="institution" key="instit2">Asklepios Klinik Altona</orgName>
								<address>
									<settlement>Hamburg</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Schmidt-Hieber</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Hematology, Oncology and Tumor Immunology</orgName>
								<address>
									<settlement>Helios-Klinikum Berlin-Buch, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">E</forename><surname>Azoulay</surname></persName>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Service de Réanimation Médicale</orgName>
								<orgName type="department" key="dep2">Faculté de Médecine</orgName>
								<orgName type="institution" key="instit1">AP-HP, Hopital Saint-Louis</orgName>
								<orgName type="institution" key="instit2">Université Paris-Diderot</orgName>
								<address>
									<settlement>Sorbonne Paris-Cité, Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Prof</roleName><forename type="middle">Georg</forename><surname>Maschmeyer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">L</forename><surname>Khoja</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology, Oncology and Palliative Care</orgName>
								<orgName type="institution">Klinikum Ernst von Bergmann</orgName>
								<address>
									<settlement>Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="institution">The Christie NHS Foundation Trust</orgName>
								<address>
									<settlement>Manchester</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Lorigan</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology, Oncology and Palliative Care</orgName>
								<orgName type="institution">Klinikum Ernst von Bergmann</orgName>
								<address>
									<settlement>Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="institution">The Christie NHS Foundation Trust</orgName>
								<address>
									<settlement>Manchester</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Dive</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Infectious Diseases</orgName>
								<orgName type="institution" key="instit1">Bellvitge University Hospital</orgName>
								<orgName type="institution" key="instit2">University of Barcelona</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff15">
								<orgName type="department">Clinical and Experimental Pharmacology</orgName>
								<orgName type="institution">The Paterson Institute for Cancer Research</orgName>
								<address>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">U</forename><surname>Keilholz</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<orgName type="institution">Mannheim University Hospital</orgName>
								<address>
									<settlement>Mannheim</settlement>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="institution">Charité Comprehensive Cancer Center</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">&amp;</forename><forename type="middle">A</forename><surname>Fusi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology, Oncology and Palliative Care</orgName>
								<orgName type="institution">Klinikum Ernst von Bergmann</orgName>
								<address>
									<settlement>Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<orgName type="institution">Mannheim University Hospital</orgName>
								<address>
									<settlement>Mannheim</settlement>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="institution">The Christie NHS Foundation Trust</orgName>
								<address>
									<settlement>Manchester</settlement>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="institution">Charité Comprehensive Cancer Center</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Alberto</forename><surname>Fusi</surname></persName>
							<email>alberto.fusi@christie.nhs.uk</email>
						</author>
						<author>
							<affiliation key="aff13">
								<orgName type="department">Department of Hematology, Oncology and Palliative Care</orgName>
								<address>
									<addrLine>Klinikum Ernst von Bergmann, Charlottenstrasse 72</addrLine>
									<postCode>D-14467</postCode>
									<settlement>Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff17">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="institution">The Christie NHS Foundation Trust</orgName>
								<address>
									<addrLine>Wilmslow Road</addrLine>
									<postCode>M20 4BX</postCode>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2014-06-06">6 June 2014</date>
						</imprint>
					</monogr>
					<idno type="MD5">5FD39A33D4406EA59BB053CC0C08861F</idno>
					<idno type="DOI">10.1093/annonc/mdu192</idno>
					<note type="submission">Received 22 February 2014; revised 29 April 2014; accepted 2 May 2014 Received 1 February 2014; revised 24 April 2014; accepted 5 May 2014</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:49+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>diagnosis</term>
					<term>fever</term>
					<term>lung infiltrates</term>
					<term>neutropenia</term>
					<term>pneumonia</term>
					<term>treatment circulating tumour cells</term>
					<term>melanoma</term>
					<term>review</term>
					<term>RT-PCR</term>
					<term>ISET</term>
					<term>immunomagnetic enrichment</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Updated overall survival (OS) analysis of novel predictive KRAS/NRAS mutations beyond KRAS exon 2 in PEAK: A 1st-line phase 2 study of FOLFOX6 plus panitumumab ( pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC).</s><s>Eur J Cancer 2013; 49: S516.</s><s>18. Ciardiello F, Lenz HJ, Kohne CH et al.</s><s>Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) † introduction consensus process See supplementary Material, available at Annals of Oncology online (Table <ref type="table">7</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>clinical baseline</head><p><s>See supplementary Material, available at Annals of Oncology online.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>diagnostic procedures</head><p><s>With respect to the critical prognosis of lung infiltrates (LI) in febrile neutropenic patients, diagnostic procedures are of major importance, but should not cause a substantial delay in the start of adequate antimicrobial therapy.</s></p><p><s>imaging Conventional chest radiographs show abnormalities in &lt;2% of febrile neutropenic patients without clinical findings indicating lower respiratory tract infection <ref type="bibr" target="#b2">[2]</ref><ref type="bibr" target="#b3">[3]</ref><ref type="bibr" target="#b4">[4]</ref>.</s><s>It is undetermined how many of these patients would have abnormalities on computed tomography (CT) scans, because no randomized head-to-head comparisons have been published so far.</s><s>In patients persistently febrile after &gt;48 h of broad-spectrum antibacterial therapy, ∼10% of chest radiographs are abnormal, whereas highresolution CT scans at this time reveal pathological findings in ∼50% of patients <ref type="bibr" target="#b5">[5,</ref><ref type="bibr" target="#b6">6]</ref>.</s><s>Early detection of lesions indicating invasive mold infection or Pneumocystis pneumonia (PcP) is of utmost importance, facilitating targeted bronchoscopy and bronchoalveolar lavage (BAL) and a prompt institution of preemptive antimicrobial treatment <ref type="bibr" target="#b7">[7]</ref><ref type="bibr" target="#b8">[8]</ref><ref type="bibr" target="#b9">[9]</ref>, enabling better survival of these patients.</s><s>CT findings such as consolidation, 'halo sign' and 'air-crescent sign', obtained by high-resolution or multislice CT scans, may be important signs of filamentous fungal disease <ref type="bibr" target="#b8">[8,</ref><ref type="bibr" target="#b10">10]</ref>.</s><s>While the 'halo sign' has been described typically in neutropenic patients, other CT findings indicative of IPA are comparable in neutropenic and in non-neutropenic patients <ref type="bibr" target="#b11">[11]</ref>.</s><s>A 'reversed halo sign', showing a focal rounded area of groundglass opacity surrounded by a crescent or complete ring of consolidation, has been reported as relatively specific for fungal pneumonia due to zygomycetes/mucorales <ref type="bibr" target="#b8">[8]</ref>; however, it may represent a broad spectrum of other differential diagnoses including tuberculosis, sarcoidosis or cryptogenic organizing pneumonia <ref type="bibr" target="#b12">[12]</ref>.</s></p><p><s>Beyond early identification of LI, CT findings may allow for distinguishing fungal from nonfungal LI <ref type="bibr" target="#b13">[13]</ref><ref type="bibr" target="#b14">[14]</ref><ref type="bibr" target="#b15">[15]</ref><ref type="bibr" target="#b16">[16]</ref><ref type="bibr" target="#b17">[17]</ref><ref type="bibr" target="#b18">[18]</ref>.</s><s>Diffuse bilateral perihilar infiltrates, patchy areas of ground-glass attenuation ( peripheral sparing), cysts and septal thickening, consolidation and centrilobular nodules may indicate PcP <ref type="bibr" target="#b19">[19]</ref><ref type="bibr" target="#b20">[20]</ref><ref type="bibr" target="#b21">[21]</ref>.</s><s>Nodular or cavitary lesions are suggestive of invasive filamentous fungal infection; however, differential diagnoses include pneumonia due to other microorganisms including mycobacteria <ref type="bibr" target="#b22">[22]</ref> (which may be relevant in regions with high prevalence), Nocardia, Pneumocystis or Pseudomonas aeruginosa (P.</s><s>aeruginosa) as well as lung involvement by underlying malignancies <ref type="bibr" target="#b23">[23]</ref>, so that comparison to previous CT scans in an individual patient is essential.</s><s>Combination of CT scan with angiography has been found to increase the diagnostic specificity in some patients with pulmonary mold infections <ref type="bibr" target="#b24">[24,</ref><ref type="bibr" target="#b25">25]</ref>; however, this more labor intensive method has not yet become widely applied and is therefore not included into current clinical practice guidelines.</s><s>In selected patients where pulmonary CT scan is not wanted or feasible, magnetic resonance tomography (MRI) is a valid alternative (B-II) <ref type="bibr" target="#b26">[26,</ref><ref type="bibr" target="#b27">27]</ref>.</s><s>As yet, consensus definitions of invasive fungal diseases <ref type="bibr" target="#b10">[10]</ref> have not included thoracic MRI findings.</s><s>In selected patients with unexplained fever during neutropenia, [ 18 F]2-fluoro-2-deoxy-D-glucose-positron emission tomography combined with computed tomography (PET-CT) may be helpful, particularly to rule out undetected infection <ref type="bibr" target="#b28">[28]</ref>.</s></p><p><s>Follow-up thoracic CT scans should in general not be ordered &lt;7 days after start of treatment (A-II).</s><s>In patients with IPA may show increasing volume of pulmonary infiltrates during the first week despite effective antifungal therapy <ref type="bibr" target="#b29">[29]</ref>.</s><s>This finding alone should not give reason to assess the treatment course as refractory (A-II).</s><s>Reduction of the 'halo' and the development of an 'aircrescent' sign, however, typically indicate favorable response <ref type="bibr" target="#b30">[30]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>microbiology and histopathology</head><p><s>In the majority of febrile neutropenic patients with LI, no proving microbiological finding is available, so that the therapeutic management is based upon clinical and imaging findings (see below).</s><s>In microbiologically documented cases, pathogens typically are isolated from blood cultures, bronchial secretions or BAL fluid.</s><s>It often means a challenge to assess the diagnostic relevance of culture results <ref type="bibr" target="#b31">[31]</ref><ref type="bibr" target="#b32">[32]</ref><ref type="bibr" target="#b33">[33]</ref><ref type="bibr" target="#b34">[34]</ref>, because unselected bronchial samples from these patients grow colonizing and contaminating microorganisms with no etiological significance <ref type="bibr" target="#b35">[35]</ref>, or blood cultures may show isolates not etiologically related to pneumonias.</s><s>At the same time, if autopsies show invasive fungal infections, 75% of them have not been detected ante mortem <ref type="bibr" target="#b36">[36,</ref><ref type="bibr" target="#b37">37]</ref>.</s><s>Therefore, in contrast to the majority of other microbiological findings, isolation of Aspergillus spp. or other filamentous fungi from upper respiratory tract specimens of severely immunocompromised patients typically indicates a respiratory tract mycosis <ref type="bibr" target="#b38">[38]</ref>.</s></p><p><s>The diagnostic yield and the outcome of clinical management in critically ill, febrile cancer patients with severe pulmonary infiltrates have not been improved by invasive diagnostic procedures including BAL <ref type="bibr" target="#b39">[39]</ref>.</s><s>The detection rate of potential pathogens from BAL samples has been described to be 25%-50% or even higher <ref type="bibr" target="#b11">[11,</ref><ref type="bibr" target="#b40">[40]</ref><ref type="bibr" target="#b41">[41]</ref><ref type="bibr" target="#b42">[42]</ref>, depending on the risk profile of patients included.</s><s>A retrospective analysis of microbiological findings from BAL samples in cancer patients with LI showed 34% bacteria, 22% cytomegalovirus (CMV), 15% Pneumocystis jirovecii (P.</s><s>jirovecii) and 2% Aspergillus spp.</s><s><ref type="bibr" target="#b43">[43]</ref>, and another report of 246 bronchoscopies in 199 febrile patients with hematological malignancies described pathogens with possible etiological significance in 48% of samples, of which 70 samples grew only bacteria, 13 showed both fungi and bacteria, 15 samples Aspergillus spp., 16 samples Candida species and 2 samples both Aspergillus and Candida spp.</s><s><ref type="bibr" target="#b33">[33]</ref>.</s><s>Many LI in severely immunocompromised patients may also have polymicrobial etiology <ref type="bibr" target="#b34">[34]</ref>, with molds ( predominantly Aspergillus spp.) plus bacteria in 12% and multiple fungal species in 22% of samples.</s><s>Although the etiological relevance of BAL findings may be questionable in many cases, the results trigger the change of antimicrobial treatment in up to 50% of patients <ref type="bibr" target="#b33">[33,</ref><ref type="bibr" target="#b44">44,</ref><ref type="bibr" target="#b45">45]</ref>.</s><s>As a diagnostic 'gold standard' is lacking, the number of false-positive and false-negative findings are unknown, and the rates of success or failure of 'pathogen-directed' antimicrobial treatment therefore remain undetermined.</s><s>A proposal for the assessment of the etiological significance of microbiological findings in febrile neutropenic patients with LI is given in antimicrobial treatment in patients with documented pathogens section.</s></p><p><s>While for the proven diagnosis of IPA, cultural isolation of fungi and histological proof from lung tissue are regarded as diagnostic 'gold standard' <ref type="bibr" target="#b10">[10]</ref>, quality standards for diagnostic procedures are not available and patients undergoing biopsy are highly selected.</s><s>Histological proof alone has an accuracy for Aspergillus of around 78%, so that histology should always be combined with fungal culture and with a culture independent method, e.g.</s><s>nucleic acid based <ref type="bibr" target="#b46">[46]</ref>.</s><s>Polymerase chain reaction (PCR) may be helpful especially in patients who already receive antifungal treatment and for difficult-to-culture pathogens such as Mucorales.</s></p><p><s>Transbronchial biopsy is not recommended in severely thrombocytopenic patients with lung infiltrates <ref type="bibr" target="#b45">[45]</ref>.</s><s>Open-lung biopsy (OLB), mini-thoracotomy or video-assisted thoracoscopic surgery may be safely carried out in patients with treatment-refractory LI not cleared-up by other diagnostic approaches, primarily in order to rule out noninfectious origin <ref type="bibr" target="#b42">[42,</ref><ref type="bibr" target="#b47">[47]</ref><ref type="bibr" target="#b48">[48]</ref><ref type="bibr" target="#b49">[49]</ref><ref type="bibr" target="#b50">[50]</ref>. OLB is a relatively safe procedure with a complication rate of ∼6% <ref type="bibr" target="#b51">[51]</ref>, including the risk of hemorrhage <ref type="bibr" target="#b49">[49,</ref><ref type="bibr" target="#b52">52]</ref> even in thrombocytopenic patients <ref type="bibr" target="#b51">[51,</ref><ref type="bibr" target="#b53">53]</ref>.</s><s>Histologically, no infection or malignancy, but nonspecific inflammation is detected in the majority of patients <ref type="bibr" target="#b31">[31,</ref><ref type="bibr" target="#b51">51,</ref><ref type="bibr" target="#b53">53]</ref>.</s><s>Notably, findings from OLB and BAL obtained simultaneously may show different microbiological results <ref type="bibr" target="#b31">[31]</ref>.</s></p><p><s>CT-guided percutaneous side-cut core needle biopsy may provide informative results in ∼80% of cases, allowing for species identification using molecular methods for tissue workup <ref type="bibr" target="#b54">[54]</ref><ref type="bibr" target="#b55">[55]</ref><ref type="bibr" target="#b56">[56]</ref><ref type="bibr" target="#b57">[57]</ref><ref type="bibr" target="#b58">[58]</ref>. Percutaneous biopsy requires platelet counts &gt;50 000/µl plus sufficient coagulation indices, e.g. an aPTT ratio of ≤1.4 <ref type="bibr" target="#b59">[59]</ref>, and should be limited to patients without an obvious risk of respiratory failure in case of complications such as a pneumothorax.</s><s>As yet, there are no reports from prospective studies comparing different methods for invasive approaches to identify the causes of LI in febrile neutropenic patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>nonculture-based diagnostic methods</head><p><s>cytomegalovirus and respiratory viruses.</s><s>In patients with profound cellular immunosuppression, respiratory viruses may be the cause of LI, so that diagnostic programs used for workup of BAL or oro-/nasopharyngeal swabs should include CMV as well as Influenza, Parainfluenza, Respiratory Syncytial Virus, Coronavirus, Rhinovirus and Human Metapneumovirus <ref type="bibr" target="#b60">[60]</ref><ref type="bibr" target="#b61">[61]</ref><ref type="bibr" target="#b62">[62]</ref><ref type="bibr" target="#b63">[63]</ref>.</s><s>In febrile neutropenic patients with LI, CMV PCR applied on BAL samples has a high negative, but low positive predictive value <ref type="bibr" target="#b64">[64]</ref>, while positive rapid culture, immediate early antigen, direct fluorescent antibody tests, DNA hybridization or cytology from BAL cultures are required to confirm the diagnosis of CMV pneumonia <ref type="bibr" target="#b65">[65,</ref><ref type="bibr" target="#b66">66]</ref>.</s></p><p><s>Pneumocystis jirovecii.</s><s>Besides microscopic identification, which has been the classical reference method for detecting P. jirovecii, PCR has been introduced in the 1990s for early detection of this pathogen with a high sensitivity <ref type="bibr" target="#b67">[67]</ref>.</s><s>It is essential to distinguish between infection and colonization, which may be present in &gt;50% of individuals without signs or symptoms of PcP <ref type="bibr" target="#b68">[68]</ref>.</s><s>A meta-analysis showed a very high sensitivity of 99% and a specificity of 90% <ref type="bibr" target="#b69">[69]</ref>, so that a negative Pneumocystis-PCR from a BAL sample at the time of diagnosis allows to put aside anti-Pneumocystis therapy <ref type="bibr" target="#b70">[70]</ref>.</s><s>More recently developed quantitative PCR assays appear to increase the specificity <ref type="bibr" target="#b71">[71,</ref><ref type="bibr" target="#b72">72]</ref>.</s><s>A report on 71 non-HIV patients with proven PcP showed a positive predictive value of 98% when &gt;1450 pathogens per ml were detected in BAL samples <ref type="bibr" target="#b73">[73]</ref>.</s><s>Determining β-D-glucan in serum may add to the differential diagnosis <ref type="bibr" target="#b74">[74,</ref><ref type="bibr" target="#b75">75]</ref>, because a negative result of this test makes PcP highly unlikely <ref type="bibr" target="#b76">[76]</ref>.</s><s>filamentous fungi.</s><s>Numerous methods have been developed for detecting fungal cell antigens such as Aspergillus galactomannan (GM), 1,3-β-D-glucan or nuclear amplification assays to identify fungal DNA for early noninvasive detection of filamentous fungi in febrile neutropenic patients with LI of undetermined etiology <ref type="bibr" target="#b77">[77]</ref><ref type="bibr" target="#b78">[78]</ref><ref type="bibr" target="#b79">[79]</ref><ref type="bibr" target="#b80">[80]</ref><ref type="bibr" target="#b81">[81]</ref>.</s><s>A positive (i.e.</s><s>&gt;0.5 OD) GM test from blood or from BAL samples, where a cutoff of ≥1.0 might be more appropriate <ref type="bibr" target="#b82">[82]</ref>, has been accepted as a significant finding indicating a probable invasive fungal infection in severely immunocompromised patients <ref type="bibr" target="#b83">[83,</ref><ref type="bibr" target="#b84">84]</ref>.</s><s>It is questionable if Aspergillus GM in blood will become positive earlier than a chest CT scan <ref type="bibr" target="#b85">[85]</ref>.</s><s>Notably, the GM test may give false-positive results in patients treated with semisynthetic β-lactam antibiotics such as amoxicillin-clavulanate, piperacillintazobactam, carbapenems, ceftriaxone or cefepime <ref type="bibr" target="#b86">[86,</ref><ref type="bibr" target="#b87">87]</ref> as well as in those given enteral nutrition <ref type="bibr" target="#b88">[88]</ref>, those with other fungal infections such as fusariosis <ref type="bibr" target="#b89">[89]</ref> and in BAL samples obtained using specific lavage solutions such as Plasmalyte™ <ref type="bibr" target="#b90">[90]</ref>.</s><s>Falsepositive Aspergillus antigenemia may also be due to blood product conditioning fluids <ref type="bibr" target="#b91">[91]</ref>.</s><s>A significant decline in the galactomannan Aspergillus antigen signal was described during storage of serum samples, in contrast to BAL samples, so that the time from taking a blood sample to testing should be minimized <ref type="bibr" target="#b92">[92]</ref>.</s></p><p><s>Details on antigen testing for fungal infection, including those other than aspergillosis <ref type="bibr" target="#b93">[93]</ref>, have been reviewed in a separate evidence-based guideline of our group <ref type="bibr" target="#b94">[94]</ref>.</s></p><p><s>Studies on panfungal or Aspergillus-specific PCR assays indicate that the use of these techniques on BAL samples seems superior when compared with blood samples, particularly in patients undergoing systemic antifungal therapy <ref type="bibr" target="#b81">[81,</ref><ref type="bibr" target="#b84">84,</ref><ref type="bibr" target="#b95">[95]</ref><ref type="bibr" target="#b96">[96]</ref><ref type="bibr" target="#b97">[97]</ref>.</s><s>On lung biopsy specimens, PCR added to histopathology and culture may improve specification of pathogens <ref type="bibr" target="#b58">[58]</ref>.</s><s>Since there is no widely accepted international standardization of these assays available as yet for blood and BAL samples <ref type="bibr" target="#b98">[98]</ref>, PCR results have not become part of definition criteria for invasive fungal infections by now <ref type="bibr" target="#b10">[10,</ref><ref type="bibr" target="#b94">94,</ref><ref type="bibr" target="#b99">99]</ref>.</s><s>PCR presumably will become part of a diagnostic program for LI, including thoracic CT scans, serology and conventional microbiology from blood and BAL samples <ref type="bibr" target="#b100">[100]</ref>.</s><s>The combination of Aspergillus PCR and GM in BAL samples enhances diagnostics since positive results for both GM and PCR make a pulmonary aspergillosis highly likely <ref type="bibr" target="#b100">[100]</ref>, as confirmed recently by meta-analyses <ref type="bibr" target="#b101">[101,</ref><ref type="bibr" target="#b102">102]</ref>.</s></p><p><s>Previous exposure to antifungal therapy may reduce the sensitivity of the galactomannan as well as quantitative PCR assays <ref type="bibr" target="#b103">[103,</ref><ref type="bibr" target="#b104">104]</ref>.</s></p><p><s>Legionella pneumophila serogroup 1 antigen.</s><s>While nosocomial outbreaks of legionellosis among cancer and leukemia patients have become very rare, a single-center report from 2007 has indicated that this differential diagnosis should not be ignored <ref type="bibr" target="#b105">[105]</ref>.</s><s>Testing of Legionella pneumophila serogroup 1 in urine helps to detect this diagnosis rapidly.</s><s>Controlled clinical studies on the usefulness of routine testing for this antigen among febrile neutropenic patients with lung infiltrates are not available.</s></p><p><s>biomarkers.</s><s>Nonspecific proinflammatory laboratory parameters like C-reactive protein, interleukin-6 <ref type="bibr" target="#b106">[106]</ref>, interleukin-8, tumor necrosis factor-α or procalcitonin plasma levels <ref type="bibr" target="#b107">[107]</ref> are frequently used to assess the severity of infections and the response to antimicrobial therapy.</s><s>In febrile neutropenic patients with LI, the predictive value of these parameters has not been investigated in prospective studies as yet.</s><s>In clinical practice, the repeated measurement of these parameters typically parallels clinical observation and should be used for therapeutic decisions only in the context with clinical and imaging findings.</s><s>Persisting fever, progressive or newly emerged LI and rising proinflammatory parameters typically indicate the need for a change in the antimicrobial treatment regimen <ref type="bibr" target="#b108">[108]</ref>.</s></p><p><s>algorithms for the clinical management of febrile neutropenic patients with LI An algorithm for the clinical management of febrile neutropenic patients with LI is proposed in Figure <ref type="figure" target="#fig_0">1</ref>.</s><s>Synopses of recommendations for diagnostic measures are given in Tables <ref type="table" target="#tab_3">1-4</ref>.</s><s>Recommendations for antimicrobial treatment and clinical management are summarized in Tables <ref type="table" target="#tab_4">5 and 6</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>diagnostic procedures</head><p><s>In patients with acute myeloid leukemia or myelodysplastic syndrome undergoing aggressive myelosuppressive chemotherapy expecting severe neutropenia lasting ≥10 days, serial monitoring of Aspergillus galactomannan from blood samples is recommended (B-II).</s><s>chemotherapy has failed to identify patients with a particularly high risk of developing invasive fungal disease <ref type="bibr" target="#b109">[109]</ref>.</s><s>Importantly, diagnostic procedures aim at obtaining microbiological results that confirm or help to modify the antimicrobial therapy, which should be initiated without awaiting results from diagnostic procedures (A-II).</s></p><p><s>Patients with fever of unknown origin not responding to an appropriate first-line therapy after 72-96 h should undergo thorough physical re-examination, imaging (Table <ref type="table" target="#tab_0">1</ref>) and microbiological diagnostics including a native thoracic CT scan and a CT scan of paranasal sinuses if symptoms or signs of sinusitis are present (A-II).</s><s>A high-resolution or multislice thoracic CT scan must be available at a maximum of 24 h after clinical indication has been established (A-II).</s><s>When LI are documented, noninvasive diagnostic tests should be repeated and bronchoscopy and BAL (Table <ref type="table" target="#tab_1">2</ref>) should be arranged within a maximum of 24 h (B-III).</s><s>BAL samples must be sent immediately to the microbiological laboratory for workup, to be started within 4 h after sampling (A-III).</s><s>Recommended microbiological procedures are listed in Table <ref type="table" target="#tab_2">3</ref>.</s><s>A standardized procedure for bronchoscopy and BAL is recommended (A-II) <ref type="bibr" target="#b111">[111]</ref>.</s></p><p><s>Invasive procedures such as open-lung or percutaneous core needle biopsy should be considered in patients with</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>antimicrobial therapy in patients without documented causative pathogens</head><p><s>Considering the dismal prognosis of febrile neutropenic patients with LI not treated promptly with an appropriate antimicrobial regimen, it is recommended to start therapy on the basis of clinical, imaging and/or laboratory findings indicative of a particular infection in patients at risk for, but without proof of this infection.</s><s>The type of underlying malignancy or immunosuppression has an instrumental impact on the selection of antimicrobial agents suitable for systemic therapy.</s><s>In patients without a conclusive microbiological finding (Table <ref type="table" target="#tab_3">4</ref>) and a lack of response to antimicrobial treatment, re-assessment including thoracic CT scan and eventually also bronchoscopy and BAL should be arranged after 7 days (A-II).</s></p><p><s>patients with severe neutropenia due to chemotherapy for acute leukemia or other aggressive hematologic malignancy.</s><s>This subgroup of febrile neutropenic patients with LI should be treated with a broad-spectrum β-lactam with antipseudomonal activity, as used for empirical treatment of fever of unknown origin (A-II).</s><s>Streptococci including cephalosporin-resistant strains <ref type="bibr" target="#b112">[112]</ref> must be included in the antimicrobial spectrum (B-II).</s><s>Additionally, patients with LI not typical for PcP or lobar bacterial pneumonia should receive mold-active systemic antifungal therapy with voriconazole or liposomal amphotericin B (A-II) <ref type="bibr" target="#b113">[113]</ref>.</s><s>This high-risk subgroup of patients has a significant benefit from prompt when compared with delayed mold-active antifungal therapy <ref type="bibr" target="#b114">[114]</ref>.</s><s>It has been shown that patients with invasive aspergillosis treated with voriconazole or liposomal amphotericin B had superior response and survival rates when treated early versus later in the course of the disease (A-II) <ref type="bibr" target="#b115">[115,</ref><ref type="bibr" target="#b116">116]</ref>.</s><s>In patients pretreated with voriconazole or posaconazole for systemic antifungal prophylaxis and in whom a breakthrough filamentous fungal pneumonia is suspected, measurement of antifungal drug levels and invasive diagnostic procedures should be taken into consideration (B-III) and treatment should be switched to liposomal amphotericin B (C-III).</s></p><p><s>Particularly in patients in whom mucormycosis (zygomycosis) is suspected, liposomal amphotericin B is recommended (A-II).</s><s>In patients without a microbiologically proven indication, the addition of an aminoglycoside or 5-flucytosine is not recommended due to a lack of benefit (E-I) <ref type="bibr" target="#b117">[117]</ref>.</s><s>In patients who had not received routine anti-Pneumocystis prophylaxis, have a thoracic CT scan suggesting PcP, and who have a rapid and otherwise unexplained rise of serum lactate dehydrogenase, prompt start of highdose trimethoprim-sulfamethoxazole (TMP/SMX) therapy should be considered before bronchoscopy and BAL (B-II) <ref type="bibr" target="#b118">[118]</ref>.</s><s>In case of PcP, BAL will remain positive for this pathogen over several days despite appropriate antimicrobial therapy <ref type="bibr" target="#b119">[119]</ref>.</s></p><p><s>Except from selected patients who also have a severe cellular immunosuppression, antiviral agents such as ganciclovir are not recommended for early pre-emptive therapy in febrile neutropenic patients with LI (E-II).</s><s>In general, glycopeptides, fluoroquinolones or macrolide antibiotics without a specific pathogen documented from clinically significant samples should not be used as well (D-III).</s></p><p><s>other subgroups of febrile patients with hematological malignancies.</s><s>In individual patients undergoing high-dose chemotherapy and autologous hematopoietic stem-cell transplantation (AHSCT) with febrile neutropenia and LI of unknown origin, whose conditioning regimen included total body irradiation or who have been treated with alemtuzumab, antithymocyte globulin or fludarabine, bronchoscopy with BAL to check for CMV disease may be considered (B-III) <ref type="bibr" target="#b120">[120]</ref>.</s><s>A positive rapid culture or 'immediate early antigen' should prompt ganciclovir treatment (5 mg/kg every 12 h) (B-III), while foscarnet has not been investigated in this setting.</s><s>Since patients after AHSCT have a very low risk of fungal pneumonia <ref type="bibr" target="#b121">[121]</ref><ref type="bibr" target="#b122">[122]</ref><ref type="bibr" target="#b123">[123]</ref>, pre-emptive antifungal therapy should not be given (D-II).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>antimicrobial treatment in patients with documented pathogens</head><p><s>The interpretation of microbiological findings in neutropenic patients with LI is difficult (Table <ref type="table" target="#tab_3">4</ref>).</s><s>Isolates typically originate from blood cultures or BAL samples.</s><s>They may represent nonpathogenic contaminants, colonizers, co-pathogens or microorganisms causing a separate infection.</s><s>If etiologically significant pathogens are detected, particularly multidrug-resistant bacteria, critical reappraisal of antimicrobial treatment to avoid fatal outcome due to delayed effective therapy is recommended (A-II) <ref type="bibr" target="#b124">[124]</ref>.</s></p><p><s>antimicrobial treatment of complicated bacterial pneumonias.</s><s>In patients with a documented P. aeruginosa pneumonia, primary combination antibacterial therapy including an antipseudomonal β-lactam plus preferably an aminoglycoside or (if an aminoglycoside is contraindicated) ciprofloxacin is recommended by many authors <ref type="bibr" target="#b125">[125]</ref><ref type="bibr" target="#b126">[126]</ref><ref type="bibr" target="#b127">[127]</ref><ref type="bibr" target="#b128">[128]</ref>.</s><s>However, meta-analyses have not unequivocally supported this recommendation <ref type="bibr" target="#b129">[129]</ref><ref type="bibr" target="#b130">[130]</ref><ref type="bibr" target="#b131">[131]</ref>, so that adequate β-lactam monotherapy may also be appropriate in this setting (B-II).</s><s>Antipseudomonal β-lactams suitable for treatment of P. aeruginosa pneumonia are piperacillin (±tazobactam), ceftazidime, imipenem/cilastatin, meropenem and cefepime (A-I).</s><s>Depending on their in vitro susceptibility pattern, multi-resistant Gram-negative aerobes such as extended-spectrum-β-lactamase-(ESBL-) producing E. coli, Enterobacter spp. or Klebsiella spp. as well as Acinetobacter spp. or P. aeruginosa require antimicrobial treatment selected appropriately according to this pattern (A-II).</s><s>Pharmacokinetic aspects (penetration to lung tissue, possible inactivation by surfactant) must always be included in this selection (A-II).</s><s>In individual patients with pneumonia caused by multi-resistant Gram-negative pathogens, aerosolized colistin has been successfully used as a part of the antimicrobial strategy <ref type="bibr" target="#b132">[132]</ref>.</s><s>Stenotrophomonas maltophilia (S. maltophilia) rarely causes pneumonia, while it is more frequently isolated from respiratory secretions representing selection of opportunistic microorganisms under broad-spectrum antibacterial treatment.</s><s>In patients with suspected or documented S. maltophilia pneumonia, early antimicrobial intervention with high-dose TMP/ SMX (15-20 mg/kg/day of trimethoprim) is recommended (B-II) <ref type="bibr" target="#b133">[133,</ref><ref type="bibr" target="#b134">134]</ref>.</s><s>In individual patients, tigecycline-based treatment may be an appropriate alternative (C-II) <ref type="bibr" target="#b135">[135]</ref>.</s><s>It should be kept in mind that in vitro susceptibility may not predict clinical efficacy of antimicrobial agents in S. maltophilia infections <ref type="bibr" target="#b136">[136]</ref>.</s></p><p><s>While pneumonia caused by methicillin-susceptible Staphylococcus aureus (S. aureus) should be treated with oxacillin or flucloxacillin, methicillin-resistant S. aureus should preferably be treated with vancomycin, if no serious renal insufficiency is present (B-II).</s><s>Linezolid is a possible alternative for first-line treatment (B-II) <ref type="bibr" target="#b137">[137]</ref><ref type="bibr" target="#b138">[138]</ref><ref type="bibr" target="#b139">[139]</ref>; however, the risk of severe thrombocytopenia or even pancytopenia associated with linezolid must be taken into consideration <ref type="bibr" target="#b140">[140]</ref>.</s><s>Daptomycin should not be used for treatment of pneumonia, because it is inactivated by surfactant (E-I) <ref type="bibr" target="#b141">[141]</ref>.</s></p><p><s>treatment of CMV pneumonia.</s><s>CMV pneumonia typically affects allogeneic stem-cell transplant recipients, but is also relevant in patients treated with lymphocyte-depleting agents like alemtuzumab or fludarabine.</s><s>First-choice antiviral treatment options are foscarnet or ganciclovir (A-II).</s><s>Foscarnet is associated with less myelosuppression, which is a serious adverse effect of ganciclovir <ref type="bibr" target="#b142">[142]</ref>.</s><s>On the other hand, reversible nephrotoxicity is one of the typical side-effects of foscarnet <ref type="bibr" target="#b143">[143]</ref>.</s></p><p><s>treatment of documented fungal pneumonia.</s><s>Detailed recommendations for treatment of documented fungal pneumonia are provided in evidence-based guidelines <ref type="bibr" target="#b113">[113,</ref><ref type="bibr" target="#b144">144,</ref><ref type="bibr" target="#b145">145]</ref>.</s><s>Intravenous voriconazole (6 mg/kg every 12 h day 1, 4 mg/kg every 12 h thereafter) (A-I) or liposomal amphotericin B (3 mg/ kg/day) (A-II) are recommended first-line choices for treatment of IPA.</s><s>For mucormycosis (zygomycosis), liposomal amphotericin B is preferred (A-II), the recommended dose is ≥5 mg/kg/day (A-II).</s><s>In patients with worsening LI and gas exchange within the first week of treatment, failure of antifungal therapy should only be considered if new LI emerge on control CT scans (B-III).</s><s>At the same time, other causes such as a second infection, immune reconstitution syndrome, infiltrates caused by the underlying malignancy, toxicity from cancer treatment or yet insufficient duration of antifungal treatment should be ruled out (B-III) <ref type="bibr" target="#b146">[146,</ref><ref type="bibr" target="#b147">147]</ref>.</s><s>Combination antifungal first-line treatment in patients with invasive mold infections is controversial.</s><s>A prospective clinical study comparing voriconazole alone with the combination of voriconazole with anidulafungin in patients with proven and probable aspergillosis has not yet been published in detail <ref type="bibr" target="#b148">[148]</ref>.</s><s>For treatment of mucormycosis, a combination of liposomal amphotericin B and an echinocandin may be promising <ref type="bibr" target="#b149">[149,</ref><ref type="bibr" target="#b150">150]</ref>; however, randomized studies on this subject have not been conducted.</s><s>A combination of liposomal amphotericin B and the iron chelator deferasirox for the treatment of mucormycoses has shown inferior clinical results for the combination when compared with the antifungal agent alone <ref type="bibr" target="#b151">[151]</ref>.</s><s>treatment of documented Pneumocystis pneumonia.</s><s>If PcP is suspected, treatment with TMP/SMX (co-trimoxazole) at a dosage of TMP 15-20 mg/kg plus SMX 75-100 mg/kg daily (A-II) should be initiated immediately after asservation of representative samples (e.g.</s><s>induced sputum or BAL) (B-II), since treatment delay may enhance mortality <ref type="bibr" target="#b152">[152,</ref><ref type="bibr" target="#b153">153]</ref>.</s><s>In mild-to-moderate cases (oxygen partial pressure pO 2 ≥70 mmHg or alveolar-arterial oxygen difference AaDO 2 &lt;45 mmHg) an oral therapy can be discussed, otherwise it should be administered i.v.</s><s>In patients with proven PcP, treatment with TMP/SMX should be continued for at least 2 weeks (A-II).</s><s>Clinical improvement should develop within 8 days, otherwise a second infection should be considered and diagnostic procedures repeated.</s><s>In individual patients with persistent PcP, mutations in the genes for dihydropteroate synthase or dihydrofolate reductase may be taken into consideration <ref type="bibr" target="#b154">[154]</ref><ref type="bibr" target="#b155">[155]</ref><ref type="bibr" target="#b156">[156]</ref><ref type="bibr" target="#b157">[157]</ref>.</s><s>In case of treatment failure or TMP/SMX intolerance, atovaquone oral suspension (750 mg twice times daily with meal), i.v.</s><s>pentamidine (4 mg/kg daily) or clindamycin (600 mg four times daily or 900 mg three times daily i.v.) plus primaquine (30 mg daily p.o.) may represent treatment alternatives <ref type="bibr" target="#b158">[158]</ref>, with clindamycin + primaquine presumably being the most effective option (C-III) <ref type="bibr" target="#b159">[159]</ref>.</s><s>Glucose-6-phosphate dehydrogenase deficiency must be excluded before administration of dapsone or primaquine (A-I).</s><s>Subsequently, patients should be given secondary prophylaxis (A-II) using oral TMP/SMX at a daily dosage of 160/800 mg given on 3 days per week (B-II) or with monthly pentamidine inhalation at a dose of 300 mg (B-II) <ref type="bibr" target="#b160">[160,</ref><ref type="bibr" target="#b161">161]</ref>.</s><s>In patients with respiratory failure due to PcP, systemic corticosteroids may be beneficial in AIDS patients, but data are conflicting in non-HIV patients <ref type="bibr" target="#b162">[162,</ref><ref type="bibr" target="#b163">163]</ref>.</s><s>Recent studies could not show a clinical benefit <ref type="bibr" target="#b164">[164]</ref> and were even associated with increased mortality <ref type="bibr" target="#b165">[165]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>intensive care medicine</head><p><s>Reports on the outcome of cancer patients requiring intensive care have shown hospital survival rates of 60%-70% and higher <ref type="bibr" target="#b166">[166]</ref><ref type="bibr" target="#b167">[167]</ref><ref type="bibr" target="#b168">[168]</ref>.</s><s>Neutropenic patients with respiratory failure due to LI may have a favorable outcome under appropriate intensive care including mechanical ventilation <ref type="bibr" target="#b169">[169]</ref><ref type="bibr" target="#b170">[170]</ref><ref type="bibr" target="#b171">[171]</ref>.</s><s>Even if respiratory failure is due to IPA, survival can be achieved in around one third of patients <ref type="bibr" target="#b172">[172]</ref>.</s><s>It is therefore not justified to reject cancer patients from intensive care only because of their underlying malignancy <ref type="bibr" target="#b173">[173]</ref>.</s><s>Multidisciplinary care involving hematology-oncology professionals should be provided during intensive care treatment of these patients (A-II).</s><s>Intensive care should unrestrictedly be provided to patients with respiratory failure (A-II), except from those whose prognosis is desperate due to other reasons or who have given a personal directive in order to abstain from it.</s><s>Circulating tumour cells (CTCs) are cells of solid tumour origin detectable in the peripheral blood.</s><s>They are considered a prerequisite step in establishing distant metastases.</s><s>CTC number has been shown to correlate with clinical outcome in several cancers including breast, prostate, colon and lung cancer <ref type="bibr" target="#b1">[1]</ref><ref type="bibr" target="#b2">[2]</ref><ref type="bibr" target="#b3">[3]</ref><ref type="bibr" target="#b4">[4]</ref><ref type="bibr" target="#b5">[5]</ref>.</s><s>In 2011, the US Food and Drug Administration approved the semi-automated and robust immunomagnetic enrichment and staining system; CellSearch™ (Veridex, Raritan, NJ), as an aid for monitoring metastatic breast, colorectal and prostatic carcinomas.</s></p><p><s>Metastatic melanoma was the first malignancy in which CTCs were detected.</s><s>Smith et al. <ref type="bibr" target="#b6">[6]</ref> reported the presence of melanoma cells in the peripheral blood of patients with metastatic cutaneous melanoma by identifying melanoma CTCs through mRNA transcript detection of specific markers.</s><s>Several studies have been published on CTC detection in melanoma at various stages of disease.</s><s>The studies reported vary considerably with respect to patient populations, timing of sampling, method of CTC detection, and assay quality control measures.</s><s>There is no general consensus as to the clinical utility of CTCs in melanoma, largely due to conflicting results in studies using differing approaches, the heterogeneity of melanoma CTCs and the scarcity of CTC analyses within prospective clinical trials.</s></p><p><s>In this review, we examine the clinical significance of CTCs in cutaneous, mucosal and ocular melanoma, focusing on detection methods, prognostic, and predictive value of CTC detection.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>materials and methods</head><p><s>We carried out a literature search using PubMed and ISI Web of Knowledge.</s><s>The key words variably combined included 'circulating tumour cells', 'CTC', 'melanoma', 'circulating melanoma cells', 'CMC' and 'prognosis'.</s><s>Only studies published in English from January 2000 till December 2013 in peer reviewed journals were considered.</s><s>For cutaneous melanoma, only studies with &gt;100 patients were reviewed for the assessment of CTC clinical significance.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Diagnostic procedures and treatment of neutropenic patients with fever and suspected or proven lung infiltrates.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>•Table 5 .</head><label>5</label><figDesc><div><p><s>Isolation of enterococci from blood culture, swabs, sputum or BAL • Coagulase-negative staphylococci or Corynebacterium spp.</s><s>obtained from any sample • Isolation of Candida spp.</s><s>from swabs, saliva, sputum or tracheal aspirates • Findings from surveillance cultures, feces and urine cultures.</s><s>'Potentially relevant' findings include: common respiratory viruses, isolation of Staphylococcus aureus, Legionella spp. or atypical mycobacteria in respiratory secretions, positive CMV-or nonquantitative Pneumocystis-PCR (without confirmation by other methods) from BAL. Recommendations for antimicrobial treatment and clinical management-I Recommendation Strength Febrile neutropenic patients with LI not typical for Pneumocystis pneumonia (PcP) or lobar bacterial pneumonia should receive mold-active systemic antifungal therapy A-II Preferred first-line therapy in this setting is voriconazole or liposomal amphotericin B A-II -Patients under current oral posa-or voriconazole prophylaxis should be switched to liposomal amphotericin B C-III The dosage of antifungal drugs in this setting is equal to the dosage used for proven mold infection B-III In severely neutropenic, hospitalized patients addressed here, antiviral agents, macrolide antibiotics, aminoglycosides or fluoroquinolones should only be given based on a conclusive microbiological finding D-II If PcP is suspected because of the pattern of lung infiltrates and new LDH elevation, treatment should be initiated also before bronchoscopy and BAL B-II Positive quantitative PCR (&gt;1450 copies/ml) for P. jirovecii from BAL should trigger the start of systemic Pneumocystis treatment B-II First choice for treatment of PcP is high-dose trimethoprim-sulfamethoxazole (TMP/SMX) A-II In PcP patients intolerant of or refractory to high-dose TMP/SMX, a combination of clindamycin plus primaquine is the preferred alternative B-II In (non-HIV) patients with critical respiratory insufficiency due to PcP, adjunctive administration of glucocorticosteroids is not generally recommended and should only be considered in individual patients C-II Patients who have been successfully treated for PcP should receive secondary oral prophylaxis to prevent PcP recurrence A-II Drugs of choice for secondary PcP prophylaxis are intermittent TMP/SMX or monthly aerosolized pentamidine B-II Independent from unequivocal documentation of pulmonary fungal infection, systemic antifungal treatment should be continued until hematopoietic recovery and regression of clinical and radiological signs of infection (B-III).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>funding</head><label></label><figDesc><div><p><s>None.</s><s>Travel expenses and costs for group meetings were reimbursed by the German Society for Hematology and Medical Oncology.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head></head><label></label><figDesc><div><p><s>disclosure GM: Consultations: Gilead; Sponsored research: Pfizer; Honoraria: Astellas, Gilead, MSD, Pfizer.</s><s>DB: Consultations: Gilead; Sponsored research: Gilead, Pfizer; Honoraria: Astellas, Gilead, Pfizer, MSD; Travel grants: Astellas, MSD, Pfizer.</s><s>AH:</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head></head><label></label><figDesc><div><p><s>introduction</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Recommendations for imaging diagnostic procedures</s></p></div></figDesc><table><row><cell>Recommendation</cell><cell>Strength</cell></row><row><cell>In febrile neutropenic patients with signs or symptoms of</cell><cell>A-II</cell></row><row><cell>lower respiratory tract infection, multislice or high-</cell><cell></cell></row><row><cell>resolution computed tomography (CT) scan of the</cell><cell></cell></row><row><cell>lungs is the diagnostic method of choice</cell><cell></cell></row><row><cell>Conventional chest radiographs are not recommended</cell><cell>E-II</cell></row><row><cell>for the diagnosis of lung infiltrates in febrile</cell><cell></cell></row><row><cell>neutropenic patients</cell><cell></cell></row><row><cell>If a pulmonary CT scan is not feasible, MRI of the lungs</cell><cell>B-II</cell></row><row><cell>is recommended</cell><cell></cell></row><row><cell>In most cases, thoracic CT scan can be done without</cell><cell>B-II</cell></row><row><cell>contrast media</cell><cell></cell></row><row><cell>Multislice or high-resolution CT scan must be available</cell><cell>A-II</cell></row><row><cell>at a maximum of 24 h after clinical indication has been</cell><cell></cell></row><row><cell>established</cell><cell></cell></row><row><cell>If infiltrates are detected on pulmonary CT scans,</cell><cell>B-III</cell></row><row><cell>bronchoalveolar lavage should be carried out at a</cell><cell></cell></row><row><cell>segmental bronchus supplying an area of radiographic</cell><cell></cell></row><row><cell>abnormalities</cell><cell></cell></row><row><cell>Whenever possible, thoracic CT showing abnormalities</cell><cell>A-II</cell></row><row><cell>scans should be compared with previous scans</cell><cell></cell></row><row><cell>CT or magnetic resonance angiography may be</cell><cell>B-III</cell></row><row><cell>considered if feeding vessel sign, reversed halo sign or</cell><cell></cell></row><row><cell>hemoptysis are observed in suspected fungal</cell><cell></cell></row><row><cell>pneumonia</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Recommendations for bronchoscopy and bronchoalveolar lavage (BAL)</s></p></div></figDesc><table><row><cell>Recommendation</cell><cell>Strength</cell></row><row><cell>Bronchoscopy and bronchoalveolar lavage should be</cell><cell>A-II</cell></row><row><cell>carried out using a standardized protocol</cell><cell></cell></row><row><cell>Transbronchial biopsies are not recommended in febrile</cell><cell>D-II</cell></row><row><cell>neutropenic (and thrombocytopenic) patients</cell><cell></cell></row><row><cell>If a tissue sample for histological, microbiological and</cell><cell>B-II</cell></row><row><cell>molecular workup is required, CT-guided side-cut</cell><cell></cell></row><row><cell>percutaneous biopsy, video-assisted thoracoscopy or</cell><cell></cell></row><row><cell>open-lung biopsy should be used</cell><cell></cell></row><row><cell>Microbiological workup of BAL samples should follow a</cell><cell>B-II</cell></row><row><cell>standardized protocol.</cell><cell></cell></row><row><cell>Bronchoscopy and BAL should be available within 24 h</cell><cell>B-III</cell></row><row><cell>after clinical indication has been established</cell><cell></cell></row><row><cell>Urgent need to start or modify antimicrobial therapy</cell><cell>A-II</cell></row><row><cell>should not be postponed by bronchoscopy and BAL</cell><cell></cell></row><row><cell>Bronchoscopy and BAL should only be carried out in</cell><cell>B-II</cell></row><row><cell>patients without critical hypoxemia</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Diagnostic workup of bronchoalveolar lavage (BAL) samples from febrile neutropenic patients with lung infiltrates</s></p></div></figDesc><table><row><cell>Recommended diagnostic program</cell><cell>Evidence</cell></row><row><cell></cell><cell>level</cell></row><row><cell>Cytospin preparations for distinguishing intracellular</cell><cell>B</cell></row><row><cell>from extracellular pathogens and identifying</cell><cell></cell></row><row><cell>infiltration by underlying malignancy</cell><cell></cell></row><row><cell>Gram stain</cell><cell>B</cell></row><row><cell>Giemsa or May-Grünwald-Giemsa stain (assessment</cell><cell>B</cell></row><row><cell>of macrophages, ciliated epithelium, leukocytes)</cell><cell></cell></row><row><cell>Mycobacterium tuberculosis (M. tuberculosis)</cell><cell>A</cell></row><row><cell>polymerase chain reaction (PCR)</cell><cell></cell></row><row><cell>PCR for Pneumocystis jirovecii (P. jirovecii);</cell><cell>A</cell></row><row><cell>quantitative if possible</cell><cell></cell></row><row><cell>Calcofluor white or equivalent (assessment of fungi</cell><cell>A</cell></row><row><cell>and P. jirovecii)</cell><cell></cell></row><row><cell>Direct immunofluorescence test for P. jirovecii</cell><cell>A</cell></row><row><cell>(confirmatory)</cell><cell></cell></row><row><cell>Aspergillus antigen (Galactomannan Sandwich</cell><cell>A</cell></row><row><cell>ELISA)</cell><cell></cell></row><row><cell>Bacteriological cultures (Quantitative or semi-</cell><cell>A</cell></row><row><cell>quantitative): dilutions of 10 −2 and 10 −4 ; culture</cell><cell></cell></row><row><cell>media: blood agar, MacConkey/Endo, Levinthal/</cell><cell></cell></row><row><cell>blood (bacterial culture), Legionella-BCYE or</cell><cell></cell></row><row><cell>equivalent (Legionella spp.), for mycobacteria at</cell><cell></cell></row><row><cell>least one solid and one liquid medium (e.g.</cell><cell></cell></row><row><cell>Löwenstein-Jensen agar and Middlebrook 7H9</cell><cell></cell></row><row><cell>broth or equivalent), Sabouraud/Kimmig or</cell><cell></cell></row><row><cell>equivalent (fungal culture)</cell><cell></cell></row><row><cell>Optional program</cell><cell></cell></row><row><cell>Enrichment culture (Brain-Heart Infusion broth,</cell><cell>C</cell></row><row><cell>dextrose broth)</cell><cell></cell></row><row><cell>Legionella PCR</cell><cell>B</cell></row><row><cell>PCR for cytomegalovirus (CMV), Respiratory</cell><cell>B</cell></row><row><cell>Syncytial Virus, influenza A/B, parainfluenza 1-3,</cell><cell></cell></row><row><cell>metapneumovirus and adenovirus</cell><cell></cell></row><row><cell>Quantitative PCR for Varicella Zoster Virus</cell><cell>B</cell></row><row><cell>Panfungal or Aspergillus PCR</cell><cell>B</cell></row><row><cell>Peripheral blood cultures 1 h after bronchoscopy to</cell><cell>C</cell></row><row><cell>detect transient bacteremia</cell><cell></cell></row><row><cell>Throat swab to assess oral flora in comparison with</cell><cell></cell></row><row><cell>BAL</cell><cell></cell></row></table><note><p><s>C Volume 26 | No. 1 | January 2015 doi:10.1093/annonc/mdu192</s><s>|  Annals of Oncology reviews undetermined LI who urgently require histological identification while bronchoscopy and BAL have failed (B-II).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4 .</head><label>4</label><figDesc><div><p><s>Clinical assessment of microbiological findings in febrile neutropenic patients with lung infiltratesThe following findings 'indicate' pathogens causative for lung infiltrates • P. jirovecii, Gram-negative aerobic pathogens, pneumococci,</s></p></div></figDesc><table><row><cell>Nocardia, M. tuberculosis or Aspergillus spp. or Aspergillus</cell></row><row><cell>galactomannan or Mucorales obtained from bronchoalveolar</cell></row><row><cell>lavage or sputum samples; positive rapid culture for CMV,</cell></row><row><cell>detection of CMV 'immediate early antigen'</cell></row><row><cell>• Isolation of pneumococci, alpha-hemolytic streptococci, Bacillus</cell></row><row><cell>cereus or Gram-negative aerobic pathogens from blood culture</cell></row><row><cell>• Any detection of pathogens with invasive growth in biopsy</cell></row><row><cell>material</cell></row><row><cell>• Positive Legionella pneumophila serogroup 1 antigen in urine</cell></row><row><cell>• Positive Aspergillus galactomannan in blood (threshold 0.5) or</cell></row><row><cell>BAL samples (cutoff of ≥1.0 might be more appropriate)</cell></row><row><cell>• Positive quantitative P. jirovecii PCR with &gt;1450 copies/ml</cell></row><row><cell>• Conversely, negative β-D-glucan in blood samples makes</cell></row><row><cell>Pneumocystis pneumonia highly unlikely</cell></row><row><cell>The following findings 'do not' represent pathogens causative for</cell></row><row><cell>lung infiltrates:</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 6 .</head><label>6</label><figDesc><div><p><s>Recommendations for antimicrobial treatment and clinical management-II</s></p></div></figDesc><table><row><cell>Recommendation</cell><cell>Strength</cell></row><row><cell>In patients with documented P. aeruginosa pneumonia,</cell><cell>B-II</cell></row><row><cell>treatment with an antipseudomonal β-lactam plus an</cell><cell></cell></row><row><cell>aminoglycoside is preferred when local in vitro</cell><cell></cell></row><row><cell>resistance patterns indicate suboptimal activity of</cell><cell></cell></row><row><cell>antipseudomonal β-lactam antibiotics</cell><cell></cell></row><row><cell>Antipseudomonal β-lactams suitable for treatment of P.</cell><cell>A-I</cell></row><row><cell>aeruginosa pneumonia are piperacillin (±tazobactam),</cell><cell></cell></row><row><cell>ceftazidime, imipenem/cilstatin, meropenem or</cell><cell></cell></row><row><cell>cefepime</cell><cell></cell></row><row><cell>In patients who cannot be treated with an</cell><cell>B-II</cell></row><row><cell>aminoglycoside, the antipseudomonal β-lactam should</cell><cell></cell></row><row><cell>be combined with ciprofloxacin</cell><cell></cell></row><row><cell>The preferred regimen for documented S. maltophilia</cell><cell>A-II</cell></row><row><cell>pneumonia is TMP/SMX</cell><cell></cell></row><row><cell>The dose of TMP/SMX for treatment of S. maltophilia</cell><cell>B-III</cell></row><row><cell>pneumonia is similar to the treatment of P. jirovecii</cell><cell></cell></row><row><cell>pneumonia</cell><cell></cell></row><row><cell>Preferred treatment regimens for CMV pneumonia are i.</cell><cell>A-II</cell></row><row><cell>v. ganciclovir or foscarnet</cell><cell></cell></row><row><cell>The selection between ganciclovir and foscarnet should</cell><cell>A-II</cell></row><row><cell>be based on the known toxicity profiles of these</cell><cell></cell></row><row><cell>compounds and, if present, known resistance patterns</cell><cell></cell></row><row><cell>Response to antimicrobial treatment should be clinically</cell><cell>A-II</cell></row><row><cell>assessed on a daily basis</cell><cell></cell></row><row><cell>Imaging studies to re-assess treatment response should</cell><cell>B-II</cell></row><row><cell>generally not be ordered earlier than after 7 days of</cell><cell></cell></row><row><cell>antimicrobial treatment</cell><cell></cell></row><row><cell>In patients with lack of clinical improvement, CT scan</cell><cell>B-II</cell></row><row><cell>should be repeated after 7 days of treatment</cell><cell></cell></row><row><cell>Persisting fever, progressive or newly emerged LI and</cell><cell>A-III</cell></row><row><cell>rising proinflammatory parameters after 7 days of</cell><cell></cell></row><row><cell>treatment typically indicate the need for repeated</cell><cell></cell></row><row><cell>microbiological diagnostics and a change in the</cell><cell></cell></row><row><cell>antimicrobial treatment regimen</cell><cell></cell></row><row><cell>Intensive care should unrestrictedly be provided to</cell><cell>A-II</cell></row><row><cell>patients with respiratory failure unless their prognosis</cell><cell></cell></row><row><cell>is desperate due to other reasons</cell><cell></cell></row><row><cell>Multidisciplinary professionals should be involved in</cell><cell>A-II</cell></row><row><cell>intensive care of cancer patients with respiratory</cell><cell></cell></row><row><cell>failure caused by lung infiltrates</cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m">Pfizer; Honoraria: Gilead, MSD, Pfizer. SN: Honoraria: MSD, MR: Consultations: Gilead; Honoraria: Gilead, Pfizer. EA: Consultations: Gilead; Sponsored research: MSD, Pfizer</title>
				<meeting><address><addrLine>Basilea, Astellas, Gilead</addrLine></address></meeting>
		<imprint/>
	</monogr>
	<note>Pfizer; Honoraria: Astellas, MSD. CPH: Consultations: MSD. All other co-authors: nothing to disclose</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategiesguidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)</title>
		<author>
			<persName><forename type="first">H</forename><surname>Einsele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bertz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Beyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Hematol</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="S175" to="S185" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Is routine chest radiography necessary for the initial evaluation of fever in neutropenic children with cancer?</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Korones</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Blood Cancer</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="715" to="717" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Conventional chest radiography in the initial assessment of adult cancer patients with fever and neutropenia</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Navigante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Cerchietti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Costantini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Control</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="346" to="351" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Routine radiography does not have a role in the diagnostic evaluation of ambulatory adult febrile neutropenic cancer patients</title>
		<author>
			<persName><forename type="first">Oude</forename><surname>Nijhuis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Gietema</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Vellenga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="2495" to="2498" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Early detection of pneumonia in febrile neutropenic patients: use of thin-section CT</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Heussel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">U</forename><surname>Kauczor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Heussel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Roentgenol</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page" from="1347" to="1353" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Heussel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">U</forename><surname>Kauczor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Heussel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="796" to="805" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients</title>
		<author>
			<persName><forename type="first">D</forename><surname>Caillot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mannone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Cuisenier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Couaillier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="54" to="61" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Georgiadou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Sipsas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Marom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Kontoyiannis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="1144" to="1155" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Bronchoscopy guided by high-resolution computed tomography for the diagnosis of pulmonary infections in patients with hematologic malignancies and normal plain chest X-ray</title>
		<author>
			<persName><forename type="first">E</forename><surname>Rámila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sureda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Martino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="961" to="966" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group Consensus Group</title>
		<author>
			<persName><forename type="first">B</forename><surname>De Pauw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Donnelly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="1813" to="1821" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey</title>
		<author>
			<persName><forename type="first">A</forename><surname>Cornillet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Camus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nimubona</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="577" to="584" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">The reversed halo sign: update and differential diagnosis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Godoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Viswanathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Marchiori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Radiol</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="1226" to="1235" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Drug-induced hypersensitivity syndrome with rapid hematopoietic reconstitution during treatment for acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">I</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Asai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Tamaki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="469" to="470" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: a useful tool for diagnosis and assessment of outcome in clinical trials</title>
		<author>
			<persName><forename type="first">D</forename><surname>Caillot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Latrabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thiébaut</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Radiol</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="e172" to="e175" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Pulmonary infections after bone marrow transplantation: high-resolution CT findings in 111 patients</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Escuissato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Gasparetto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Marchiori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Roentgenol</title>
		<imprint>
			<biblScope unit="volume">185</biblScope>
			<biblScope unit="page" from="608" to="615" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">High-resolution CT findings of respiratory syncytial virus pneumonia after bone marrow transplantation</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Gasparetto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Escuissato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Marchiori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Roentgenol</title>
		<imprint>
			<biblScope unit="volume">182</biblScope>
			<biblScope unit="page" from="1133" to="1137" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Clinical and radiologic predictors of invasive pulmonary aspergillosis in cancer patients: should the European Organization for Research and Treatment of Cancer/Mycosis Study Group criteria be revised?</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hachem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sumoza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hanna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="1581" to="1586" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Pneumonia in neutropenic patients</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Heussel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">U</forename><surname>Kauczor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Ullmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Radiol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="256" to="271" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Pneumocystis jiroveci pneumonia: highresolution CT findings in patients with and without HIV infection</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Kanne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Yandow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Meyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AJR Am J Roentgenol</title>
		<imprint>
			<biblScope unit="volume">198</biblScope>
			<biblScope unit="page" from="W555" to="W561" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Comparison of clinical and radiological features of Pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases: a multicenter study</title>
		<author>
			<persName><forename type="first">S</forename><surname>Tasaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tokuda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sakai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Intern Med</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="273" to="281" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Vogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vatlach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Weissgerber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Radiol</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="1315" to="1320" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: how firm is the Aspergillus diagnosis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Georgiadou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Kontoyiannis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="262" to="268" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Pulmonary infiltrates in the non-HIV-infected immunocompromised patient: etiologies, diagnostic strategies, and outcomes</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Shorr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Susla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Grady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="260" to="271" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Direct detection of angioinvasive pulmonary aspergillosis in immunosuppressed patients: preliminary results with high-resolution 16-MDCT angiography</title>
		<author>
			<persName><forename type="first">S</forename><surname>Sonnet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Buitrago-Téllez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tamm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AJR Am J Roentgenol</title>
		<imprint>
			<biblScope unit="volume">184</biblScope>
			<biblScope unit="page" from="746" to="751" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Stanzani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Battista</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sassi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="610" to="616" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">3Tesla proton MRI for the diagnosis of pneumonia/lung infiltrates in neutropenic patients with acute myeloid leukemia: initial results in comparison to HRCT</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">I</forename><surname>Attenberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Morelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Henzler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Radiol</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="e61" to="e66" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Pulmonary abnormalities in immunocompromised patients: comparative detection with parallel acquisition MR imaging and thin-section helical CT</title>
		<author>
			<persName><forename type="first">R</forename><surname>Eibel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Herzog</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Dietrich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiology</title>
		<imprint>
			<biblScope unit="volume">241</biblScope>
			<biblScope unit="page" from="880" to="891" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">18F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Vos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Donnelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Oyen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="120" to="128" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia</title>
		<author>
			<persName><forename type="first">D</forename><surname>Caillot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Couaillier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bernard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="253" to="259" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Brodoefel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hebart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Roentgenol</title>
		<imprint>
			<biblScope unit="volume">187</biblScope>
			<biblScope unit="page" from="404" to="413" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Open lung biopsy provides a higher and more specific diagnostic yield compared to bronchoalveolar lavage in immunocompromised patients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Spence</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bouchama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="157" to="162" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Diagnostic bronchoscopy in hematology and oncology patients with acute respiratory failure</title>
		<author>
			<persName><forename type="first">E</forename><surname>Azoulay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mokart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rabbat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="100" to="107" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Diagnostic yield of bronchoscopy with bronchoalveolar lavage in febrile patients with hematologic malignancies and pulmonary infiltrates</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hummel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rudert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hof</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Hematol</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="291" to="297" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Polymicrobial infection in patients with cancer: an underappreciated and underreported entity</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Rolston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Bodey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Safdar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="228" to="233" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Surveillance of nosocomial sepsis and pneumonia in patients with a bone marrow or peripheral blood stem cell transplant</title>
		<author>
			<persName><forename type="first">M</forename><surname>Dettenkofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wenzler-Rottele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Babikir</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="926" to="931" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period</title>
		<author>
			<persName><forename type="first">G</forename><surname>Chamilos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Luna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Lewis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="986" to="989" />
			<date type="published" when="1989">1989-2003. 2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings</title>
		<author>
			<persName><forename type="first">S</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Nadrous</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Peters</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="1385" to="1392" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Perfect</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Cox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1824" to="1833" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Diagnostic strategy for hematology and oncology patients with acute respiratory failure: randomized controlled trial</title>
		<author>
			<persName><forename type="first">E</forename><surname>Azoulay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mokart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lambert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">182</biblScope>
			<biblScope unit="page" from="1038" to="1046" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Bronchoscopic diagnosis of pulmonary infiltrates in granulocytopenic patients with hematologic malignancies: BAL versus PSB and PBAL</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Boersma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Erjavec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Van Der Werf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Respir Med</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="317" to="325" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Role of flexible bronchoscopy in immunocompromised patients with lung infiltrates</title>
		<author>
			<persName><forename type="first">P</forename><surname>Jain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sandur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Meli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="712" to="722" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Surgical lung biopsy in patients with hematological malignancy or hematopoietic stem cell transplantation and unexplained pulmonary infiltrates: improved outcome with specific diagnosis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Zihlif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Khanchandani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">O</forename><surname>Soubani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Hematol</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="94" to="99" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Pulmonary infiltrates in patients with haematologic malignancies: transbronchial lung biopsy increases the diagnostic yield with respect to neoplastic infiltrates and toxic pneumonitis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mulabecirovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gaulhofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Auner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Hematol</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="420" to="422" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">The influence of diagnostic bronchoscopy on clinical outcomes comparing adult autologous and allogeneic bone marrow transplant patients</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="1388" to="1396" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Safety, diagnostic yield, and therapeutic implications of flexible bronchoscopy in patients with febrile neutropenia and pulmonary infiltrates</title>
		<author>
			<persName><forename type="first">T</forename><surname>Peikert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Edell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mayo Clin Proc</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="1414" to="1420" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Diagnostic accuracy of histopathologic and cytopathologic examination of Aspergillus species</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Hazen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="55" to="61" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Organizing pneumonia in patients with hematologic malignancies: a steroid-responsive lesion</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Daniels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Myers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Utz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Respir Med</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="162" to="168" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Drug-induced respiratory disease in patients with hematological diseases</title>
		<author>
			<persName><forename type="first">P</forename><surname>Camus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Costabel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="458" to="481" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Evaluation of persistent pulmonary infiltrates in pediatric oncology patients</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Armenian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">La</forename><surname>Via</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">V</forename><surname>Siegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Mascarenhas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Blood Cancer</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="165" to="172" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Surgical management of invasive pulmonary fungal infection in hematology patients</title>
		<author>
			<persName><forename type="first">S</forename><surname>Theodore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Liava'a</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Antippa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Thorac Surg</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="1532" to="1538" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Open-lung biopsy in patients with undiagnosed lung lesions referred at a tertiary cancer center is safe and reveals noncancerous, noninfectious entities as the most common diagnoses</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Georgiadou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Sampsonas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rice</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="101" to="105" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">The utility of open lung biopsy in patients with hematologic malignancies</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Downey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="page" from="723" to="729" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Accuracy of percutaneous lung biopsy for invasive pulmonary aspergillosis</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Hoffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Flynn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Davidoff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Radiol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="144" to="152" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Utility of computed tomography and of fine needle aspiration biopsy in early diagnosis of fungal pulmonary infections</title>
		<author>
			<persName><forename type="first">G</forename><surname>Carrafiello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lagana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Nosari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiol Med</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="33" to="41" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">CT-guided percutaneous lung biopsies in patients with haematologic malignancies and undiagnosed pulmonary lesions</title>
		<author>
			<persName><forename type="first">S</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sultenfuss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Romaguera</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hematol Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="75" to="81" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">The value of computed tomographyguided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients</title>
		<author>
			<persName><forename type="first">C</forename><surname>Lass-Flörl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Resch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nachbaur</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="e101" to="e104" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Aspergillus PCR-based investigation of fresh tissue and effusion samples in patients with suspected invasive Aspergillosis enhances diagnostic capabilities</title>
		<author>
			<persName><forename type="first">M</forename><surname>Reinwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Spiess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Heinz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="4178" to="4185" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens</title>
		<author>
			<persName><forename type="first">V</forename><surname>Rickerts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mousset</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lambrecht</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="1078" to="1083" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Guidelines for radiologically guided lung biopsy</title>
		<author>
			<persName><forename type="first">A</forename><surname>Manhire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Charig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Clelland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thorax</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="920" to="936" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Chemaly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Hanmod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Rathod</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="2738" to="2745" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Hirsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Martino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Ward</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Fourth European Conference on Infections in Leukaemia</title>
				<imprint>
			<date type="published" when="2013">2013</date>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="258" to="266" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Human metapneumovirus infection in hematopoietic stem cell transplant recipients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Debur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Vidal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Stroparo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Infect Dis</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="173" to="179" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Martino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Rabella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">192</biblScope>
			<biblScope unit="page" from="1061" to="1065" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Bronchoalveolar lavage in immunocompromised patients with haematological malignancy-value of new microbiological methods</title>
		<author>
			<persName><forename type="first">U</forename><surname>Hohenthal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Itälä</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Salonen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Haematol</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="203" to="211" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Complications, diagnosis, management, and prevention of CMV infections: current and future</title>
		<author>
			<persName><forename type="first">M</forename><surname>Boeckh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hematology Am Soc Hematol Educ Program</title>
		<imprint>
			<biblScope unit="volume">2011</biblScope>
			<biblScope unit="page" from="305" to="309" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Definitions of cytomegalovirus infection and disease in transplant recipients</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ljungman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Griffiths</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Paya</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1094" to="1097" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Evaluation of diagnostic value and epidemiological implications of PCR for Pneumocystis carinii in different immunosuppressed and immunocompetent patient groups</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Trebesius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Roggenkamp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1461" to="1467" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Ponce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gallo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bustamante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Vargas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="347" to="353" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">PCR diagnosis of Pneumocystis pneumonia: a bivariate meta-analysis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Qiang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="4361" to="4363" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Polymerase chain reaction for diagnosing Pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates</title>
		<author>
			<persName><forename type="first">E</forename><surname>Azoulay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bergeron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chevret</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="655" to="661" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients</title>
		<author>
			<persName><forename type="first">A</forename><surname>Alanio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Desoubeaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sarfati</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1531" to="1537" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Outcome of Pneumocystis jirovecii pneumonia diagnosed by polymerase chain reaction in patients without human immunodeficiency virus infection</title>
		<author>
			<persName><forename type="first">E</forename><surname>Hardak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Neuberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yigla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Respirology</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="681" to="686" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Quantitative PCR to diagnose Pneumocystis pneumonia in immunocompromised non-HIV patients</title>
		<author>
			<persName><forename type="first">K</forename><surname>Mühlethaler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bögli-Stuber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wasmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Respir J</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="971" to="978" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Diagnostic accuracy of serum 1,3-β-D-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Onishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sugiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kogata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="7" to="15" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Detection of (1, 3)-β-D-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Theel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Jespersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Iqbal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mycopathologia</title>
		<imprint>
			<biblScope unit="volume">175</biblScope>
			<biblScope unit="page" from="33" to="41" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Accuracy of β-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Karageorgopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Qu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">P</forename><surname>Korbila</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="39" to="49" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Busca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Locatelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Barbui</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplant Proc</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1610" to="1613" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Detection and identification of fungal pathogens in blood by using molecular probes</title>
		<author>
			<persName><forename type="first">H</forename><surname>Einsele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hebart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Roller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1353" to="1360" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Maertens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Verhaegen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Demuynck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="3223" to="3228" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Maertens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Klont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Masson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="1329" to="1336" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Development of a LightCycler PCR assay for detection and quantification of Aspergillus fumigatus DNA in clinical samples from neutropenic patients</title>
		<author>
			<persName><forename type="first">B</forename><surname>Spiess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Buchheidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Baust</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="1811" to="1818" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Zou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">e43347</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Lugtenburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Cornelissen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="448" to="457" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Detection of Aspergillus species in blood and bronchoalveolar lavage samples from immunocompromised patients by means of 2-step polymerase chain reaction: clinical results</title>
		<author>
			<persName><forename type="first">D</forename><surname>Buchheidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Baust</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Skladny</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="428" to="435" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Weisser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rausch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Droll</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="1143" to="1149" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders</title>
		<author>
			<persName><forename type="first">A</forename><surname>Aubry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Porcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bottero</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="389" to="394" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Falsepositive serum and bronchoalveolar lavage Aspergillus galactomannan assays caused by different antibiotics</title>
		<author>
			<persName><forename type="first">V</forename><surname>Boonsarngsuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Niyompattama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Teosirimongkol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sriwanichrak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="461" to="468" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Enteral nutrition may cause false-positive results of Aspergillus galactomannan assay in absence of gastrointestinal diseases</title>
		<author>
			<persName><forename type="first">C</forename><surname>Girmenia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Santilli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ballarò</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mycoses</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="e883" to="e884" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Cross-reactivity of Fusarium spp. in the Aspergillus galactomannan enzyme-linked immunosorbent assay</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Tortorano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Esposto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Prigitano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="1051" to="1053" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Plasmalyte as a cause of false-positive results for Aspergillus galactomannan in bronchoalveolar lavage fluid</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Hage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Reynolds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Durkin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="676" to="677" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">False-positive Aspergillus antigenemia due to blood product conditioning fluids</title>
		<author>
			<persName><forename type="first">P</forename><surname>Martín-Rabadán</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gijón</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alonso</forename><surname>Fernández</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="e22" to="e27" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Significant decline in galactomannan signal during storage of clinical serum samples</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Sarker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Mol Sci</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="12970" to="12977" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Multicenter clinical evaluation of the (1,3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ostrosky-Zeichner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Kett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="654" to="659" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Diagnosis of invasive fungal infections in hematology and oncology guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ruhnke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Böhme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Buchheidt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="823" to="833" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Diagnosing invasive aspergillosis during antifungal therapy by PCR analysis of blood samples</title>
		<author>
			<persName><forename type="first">C</forename><surname>Lass-Flörl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gunsilius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gastl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="4154" to="4157" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">The value of CMV and fungal PCR for monitoring for acute leukaemia and autologous stem cell transplant patients</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ljungman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Von Dobeln</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ringholm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="121" to="127" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid</title>
		<author>
			<persName><forename type="first">B</forename><surname>Musher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Fredricks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Leisenring</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="5517" to="5522" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Aspergillus PCR: one step closer to standardization</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bretagne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Klingspor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1231" to="1240" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Mengoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cruciani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Barnes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="89" to="96" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Linton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Perry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="479" to="486" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review</title>
		<author>
			<persName><forename type="first">T</forename><surname>Avni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sprecher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="3652" to="3658" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Heng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Morrissey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Chen</surname></persName>
		</author>
		<idno>doi: 10.3109/ 1040841X.2013.804033</idno>
	</analytic>
	<monogr>
		<title level="j">Crit Rev Microbiol</title>
		<imprint>
			<date type="published" when="2013-06-25">2013 June 25</date>
		</imprint>
	</monogr>
	<note>epub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Marr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Laverdiere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gugel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Leisenring</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1762" to="1769" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Mcculloch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ramage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rajendran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="83" to="86" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Outbreak of Legionnaires&apos; disease in immunosuppressed patients at a cancer centre: usefulness of universal urine antigen testing and early levofloxacin therapy</title>
		<author>
			<persName><forename type="first">C</forename><surname>Gudiol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Verdaguer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Angeles</forename><surname>Domínguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1125" to="1128" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Markers of bacteremia in febrile neutropenic patients with haematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein</title>
		<author>
			<persName><forename type="first">M</forename><surname>Von Lilienfeld-Toal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Dietrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Glasmacher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="539" to="544" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Procalcitonin as a specific marker of bacterial infection in adults</title>
		<author>
			<persName><forename type="first">G</forename><surname>Monneret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Doche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">V</forename><surname>Durand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem Lab Med</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="67" to="68" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever?</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lamoth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bally</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">e18886</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Maschmeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Heinz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hertenstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="679" to="689" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">Infectious Diseases Society of America. Guide to development of practice guidelines</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Kish</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="851" to="854" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: a prospective 2-year study</title>
		<author>
			<persName><forename type="first">F</forename><surname>Sampsonas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Kontoyiannis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Dickey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Evans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="3424" to="3433" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome</title>
		<author>
			<persName><forename type="first">J</forename><surname>Carratalà</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rosón</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fernández-Sevilla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">158</biblScope>
			<biblScope unit="page" from="868" to="872" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Anaissie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Denning</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="327" to="360" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients</title>
		<author>
			<persName><forename type="first">X</forename><surname>Schiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Link</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Maschmeyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infection</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="118" to="126" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">A</forename><surname>Cornely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Maertens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bresnik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mycoses</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="e449" to="e455" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Greene</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename><surname>Schlamm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Oestmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="373" to="379" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Soares-Weiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Leibovici</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">326</biblScope>
			<biblScope unit="page" from="1111" to="1119" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Analysis of clinical features of non-HIV Pneumocystis jirovecii pneumonia</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Ainoda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hirai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fujita</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Chemother</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="722" to="728" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">Persistence of Pneumocystis carinii after effective treatment of P. carinii pneumonia is not related to relapse or survival among patients infected with human immunodeficiency virus</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Roger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Vandenbos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pugliese</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="509" to="510" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Fassas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bolaños-Meade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">N</forename><surname>Buddharaju</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="237" to="241" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study</title>
		<author>
			<persName><forename type="first">L</forename><surname>Pagano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Caira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nosari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1161" to="1170" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">Invasive fungal infections in allogeneic and autologous stem cell transplant recipients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Post</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lass-Floerl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gastl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nachbaur</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Infect Dis</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="189" to="195" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">Infectious complications after high-dose chemotherapy and autologous stem cell transplantation</title>
		<author>
			<persName><forename type="first">G</forename><surname>Reich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Mapara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Reichardt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="525" to="529" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamaseproducing enterobacteriaceae: variability by site of infection</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Hyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Lipworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Zaoutis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">165</biblScope>
			<biblScope unit="page" from="1375" to="1380" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy</title>
		<author>
			<persName><forename type="first">J</forename><surname>Garnacho-Montero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sa-Borges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sole-Violan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1888" to="1895" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Moon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">308</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis</title>
		<author>
			<persName><forename type="first">N</forename><surname>Safdar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Handelsman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Maki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="519" to="527" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">Clinical approach to the patient with suspected ventilator-associated pneumonia</title>
		<author>
			<persName><forename type="first">L</forename><surname>Vidaur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sirgo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Rodríguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rello</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Respir Care</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="965" to="974" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes</title>
		<author>
			<persName><forename type="first">I</forename><surname>Chatzinikolaou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Abi-Said</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Bodey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">160</biblScope>
			<biblScope unit="page" from="501" to="509" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post hoc analysis of a prospective cohort</title>
		<author>
			<persName><forename type="first">C</forename><surname>Peña</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Suarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ocampo-Sosa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="208" to="216" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">Falagas ME. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Z</forename><surname>Vardakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Tansarli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">A</forename><surname>Bliziotis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="301" to="310" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main">Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Michalopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Kasiakou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Mastora</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Care</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="R53" to="R59" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection</title>
		<author>
			<persName><forename type="first">G</forename><surname>Aisenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Rolston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Dickey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="13" to="20" />
			<date type="published" when="1997">1997-2004. 2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main">Stenotrophomonas maltophilia infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhage</title>
		<author>
			<persName><forename type="first">K</forename><surname>Tada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kurosawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hiramoto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="74" to="79" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Tekçe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Erbay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Cabadak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Chemother</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="150" to="154" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main">Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Carroll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nelson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diagn Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="229" to="235" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Kalil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Klompas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Haynatzki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Rupp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">e003912</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main">Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Walkey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>O'donnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Wiener</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="1148" to="1155" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Wunderink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Cammarata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="1789" to="1797" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">Linezolid-related pancytopenia in organtransplant patients: report of two cases</title>
		<author>
			<persName><forename type="first">S</forename><surname>Faguer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kamar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Fillola</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infection</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="275" to="277" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main">Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Silverman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">I</forename><surname>Mortin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Vanpraagh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">191</biblScope>
			<biblScope unit="page" from="2149" to="2152" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main">Cytomegalovirus infection/disease after hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">T</forename><surname>Mori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Hematol</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="588" to="595" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main">A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Wagstaff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Bryson</surname></persName>
		</author>
		<author>
			<persName><surname>Foscarnet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drugs</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="199" to="226" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b144">
	<analytic>
		<title level="a" type="main">American Thoracic Society Fungal Working Group. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Limper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Knox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Sarosi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">183</biblScope>
			<biblScope unit="page" from="96" to="128" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main">Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mousset</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Buchheidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Heinz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Hematol</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="13" to="32" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b146">
	<analytic>
		<title level="a" type="main">Defining clinical failure for salvage studies</title>
		<author>
			<persName><forename type="first">G</forename><surname>Maschmeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Haas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Mycol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="S315" to="S318" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b147">
	<analytic>
		<title level="a" type="main">Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Segal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Herbrecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Stevens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="674" to="683" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b148">
	<analytic>
		<title level="a" type="main">A Randomised, Double-Blind Study of Combination Antifungal Therapy with Voriconazole and Anidulafungin Versus Voriconazole Monotherapy for Primary Treatment of Invasive Aspergillosis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Marr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Schlamm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Rottinghaus</surname></persName>
		</author>
		<idno>abstr #LB2812</idno>
	</analytic>
	<monogr>
		<title level="m">22nd European Congress of Clinical Microbiology and Infectious Diseases</title>
				<meeting><address><addrLine>London, UK</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2012-04-03">31 March-3 April 2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b149">
	<analytic>
		<title level="a" type="main">Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Reed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bryant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Ibrahim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="364" to="371" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b150">
	<analytic>
		<title level="a" type="main">Combination therapy for mucormycosis: why, what, and how?</title>
		<author>
			<persName><forename type="first">B</forename><surname>Spellberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ibrahim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Roilides</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="S73" to="S78" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b151">
	<analytic>
		<title level="a" type="main">The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial</title>
		<author>
			<persName><forename type="first">B</forename><surname>Spellberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Ibrahim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">V</forename><surname>Chin-Hong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="715" to="722" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b152">
	<analytic>
		<title level="a" type="main">Early diagnosis and treatment are crucial for the survival of Pneumocystis pneumonia patients without human immunodeficiency virus infection</title>
		<author>
			<persName><forename type="first">N</forename><surname>Asai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Motojima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ohkuni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Chemother</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="898" to="905" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b153">
	<analytic>
		<title level="a" type="main">Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIVinfected individuals</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Microbiol Immunol Infect</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="42" to="47" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b154">
	<analytic>
		<title level="a" type="main">High prevalence of dihydropteroate synthase mutations in Pneumocystis jirovecii isolated from patients with Pneumocystis pneumonia in South Africa</title>
		<author>
			<persName><forename type="first">L</forename><surname>Dini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Du Plessis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Frean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Fernandez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="2016" to="2021" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b155">
	<analytic>
		<title level="a" type="main">Circulation of Pneumocystis dihydropteroate synthase mutants in France</title>
		<author>
			<persName><forename type="first">Le</forename><surname>Gal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Damiani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Perrot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diagn Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="119" to="124" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b156">
	<analytic>
		<title level="a" type="main">Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency viruspositive and -negative patients</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nahimana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rabodonirina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Zanetti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">188</biblScope>
			<biblScope unit="page" from="1017" to="1023" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b157">
	<analytic>
		<title level="a" type="main">Trimethoprim resistance of dihydrofolate reductase (DHFR) variants from clinical isolates of Pneumocystis jirovecii</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Queener</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Cody</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pace</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="4990" to="4998" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b158">
	<analytic>
		<title level="a" type="main">Pneumocystis pneumonia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Limper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">350</biblScope>
			<biblScope unit="page" from="2487" to="2498" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b159">
	<analytic>
		<title level="a" type="main">A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Smego</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nagar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Maloba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Popara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="page" from="1529" to="1533" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b160">
	<analytic>
		<title level="a" type="main">Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Rivera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Schell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">316</biblScope>
			<biblScope unit="page" from="1627" to="1632" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b161">
	<analytic>
		<title level="a" type="main">A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Hoepelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Eeftinck</forename><surname>Schattenkerk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">327</biblScope>
			<biblScope unit="page" from="1836" to="1841" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b162">
	<analytic>
		<title level="a" type="main">Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virusinfected patients</title>
		<author>
			<persName><forename type="first">C</forename><surname>Delclaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Zahar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Amraoui</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="670" to="672" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b163">
	<analytic>
		<title level="a" type="main">Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Pareja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Garland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Koziel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="1215" to="1224" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b164">
	<analytic>
		<title level="a" type="main">Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Moon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="4613" to="4618" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b165">
	<analytic>
		<title level="a" type="main">Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia</title>
		<author>
			<persName><forename type="first">V</forename><surname>Lemiale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Debrumetz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Delannoy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Respir Res</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">87</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b166">
	<analytic>
		<title level="a" type="main">Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium-a groupe de recherche respiratoire en reanimation oncohematologique study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Azoulay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mokart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pène</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="2810" to="2818" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b167">
	<analytic>
		<title level="a" type="main">Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: a 5 yr study</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Bird</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Farquhar-Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Wigmore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Anaesth</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="452" to="459" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b168">
	<analytic>
		<title level="a" type="main">Characteristics and outcomes of cancer patients in European ICUs</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Taccone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Artigas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Sprung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Care</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">R15</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b169">
	<analytic>
		<title level="a" type="main">Predictors of short and long-term outcome in patients with hematological disorders admitted to the intensive care unit for a life-threatening complication</title>
		<author>
			<persName><forename type="first">H</forename><surname>Cherif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Martling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hansen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Support Care Cancer</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1393" to="1398" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b170">
	<analytic>
		<title level="a" type="main">Outcome analysis of 189 consecutive cancer patients referred to the intensive care unit as emergencies during a 2-year period</title>
		<author>
			<persName><forename type="first">G</forename><surname>Maschmeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Bertschat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Moesta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="783" to="792" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b171">
	<analytic>
		<title level="a" type="main">Patients with haematological malignancies requiring invasive mechanical ventilation: differences between survivors and non-survivors in intensive care unit</title>
		<author>
			<persName><forename type="first">R</forename><surname>Owczuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Wujtewicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sawicka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Support Care Cancer</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="332" to="338" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b172">
	<analytic>
		<title level="a" type="main">Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Burghi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Lemiale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Seguin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Intensive Care Med</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1605" to="1612" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b173">
	<analytic>
		<title level="a" type="main">Intensive care and oncology</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Sculier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Support Care Cancer</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="93" to="105" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
